DK3132791T3 - Inhibition of Metastases with Compounds That Reduce the Persistent Part of the Voltage-Dependent Sodium Channel - Google Patents

Inhibition of Metastases with Compounds That Reduce the Persistent Part of the Voltage-Dependent Sodium Channel Download PDF

Info

Publication number
DK3132791T3
DK3132791T3 DK16020321.2T DK16020321T DK3132791T3 DK 3132791 T3 DK3132791 T3 DK 3132791T3 DK 16020321 T DK16020321 T DK 16020321T DK 3132791 T3 DK3132791 T3 DK 3132791T3
Authority
DK
Denmark
Prior art keywords
metastases
inhibition
compounds
voltage
reduce
Prior art date
Application number
DK16020321.2T
Other languages
Danish (da)
Inventor
Mustafa Bilgin Ali Djamgoz
Original Assignee
Celex Oncology Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celex Oncology Innovations Ltd filed Critical Celex Oncology Innovations Ltd
Application granted granted Critical
Publication of DK3132791T3 publication Critical patent/DK3132791T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16020321.2T 2010-10-13 2010-10-13 Inhibition of Metastases with Compounds That Reduce the Persistent Part of the Voltage-Dependent Sodium Channel DK3132791T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16020321.2A EP3132791B1 (en) 2010-10-13 2010-10-13 Inhibition of metastasis by compounds which reduce the persistent part of the voltage-gated sodium channel
EP10776791.5A EP2627321A1 (en) 2010-10-13 2010-10-13 Treatment of cancer/inhibition of metastasis
PCT/GB2010/001908 WO2012049440A1 (en) 2010-10-13 2010-10-13 Treatment of cancer/inhibition of metastasis

Publications (1)

Publication Number Publication Date
DK3132791T3 true DK3132791T3 (en) 2020-03-09

Family

ID=44022817

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16020321.2T DK3132791T3 (en) 2010-10-13 2010-10-13 Inhibition of Metastases with Compounds That Reduce the Persistent Part of the Voltage-Dependent Sodium Channel

Country Status (13)

Country Link
US (5) US20130203764A1 (en)
EP (3) EP3132791B1 (en)
JP (1) JP2013539778A (en)
KR (1) KR20140032346A (en)
CN (2) CN112755029A (en)
AU (2) AU2010362412A1 (en)
BR (1) BR112013009086A2 (en)
CA (1) CA2851694C (en)
DK (1) DK3132791T3 (en)
IL (1) IL225689A0 (en)
RU (1) RU2013121744A (en)
SG (1) SG189352A1 (en)
WO (1) WO2012049440A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3132791B1 (en) 2010-10-13 2019-11-27 Celex Oncology Innovations Limited Inhibition of metastasis by compounds which reduce the persistent part of the voltage-gated sodium channel
WO2013123403A1 (en) * 2012-02-15 2013-08-22 Sanford-Burnham Medical Research Institute Theranostics platform and methods of use
WO2017091574A1 (en) * 2015-11-25 2017-06-01 Health Research, Inc. Riluzole and riluzole drug combinations for the treatment of prostate cancer
JP6465306B2 (en) * 2016-02-04 2019-02-06 セレックス・オンコロジー・リミテッド Cancer treatment / inhibition of metastasis
CN110662545A (en) * 2017-02-10 2020-01-07 赛立斯肿瘤学创新有限公司 Cancer treatment and metastasis inhibition
US20200123544A1 (en) * 2018-10-22 2020-04-23 Celex Oncology Innovations Limited Gene therapy targeting the neonatal form of nav1.5 for treating cancer
KR20220087509A (en) 2019-10-24 2022-06-24 셀렉스 온콜로지 이노베이션즈 리미티드 Combination treatment of cancer
EP4093769A1 (en) 2020-01-21 2022-11-30 Celex Oncology Innovations Limited Monoclonal antibodies against neonatal nav1.5
US20230139204A1 (en) 2020-03-09 2023-05-04 Celex Oncology Innovations Limited Measuring electric activity of cells for the evaluation of metastatic potential of cancer cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1659136A (en) * 2002-04-18 2005-08-24 弗吉尼亚大学专利基金会 Novel sodium channel blockers
US6979675B2 (en) * 2003-01-10 2005-12-27 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US8835473B2 (en) * 2004-04-16 2014-09-16 Rutgers, The State University Of New Jersey Methods and compositions for treating cancer
WO2009105230A2 (en) * 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
US20110251144A1 (en) * 2008-09-16 2011-10-13 Massachusetts Institute Of Technology Molecular modulators of the wnt/beta-catenin pathway
EP3132791B1 (en) 2010-10-13 2019-11-27 Celex Oncology Innovations Limited Inhibition of metastasis by compounds which reduce the persistent part of the voltage-gated sodium channel

Also Published As

Publication number Publication date
CN103370060A (en) 2013-10-23
KR20140032346A (en) 2014-03-14
JP2013539778A (en) 2013-10-28
US20200017457A1 (en) 2020-01-16
AU2017202267B2 (en) 2019-01-24
EP3132791B1 (en) 2019-11-27
US11634398B2 (en) 2023-04-25
WO2012049440A1 (en) 2012-04-19
US20180346431A1 (en) 2018-12-06
CA2851694A1 (en) 2012-04-19
CN112755029A (en) 2021-05-07
AU2010362412A1 (en) 2013-05-30
US20230202994A1 (en) 2023-06-29
BR112013009086A2 (en) 2016-07-26
CA2851694C (en) 2019-02-26
SG189352A1 (en) 2013-05-31
US20160096812A1 (en) 2016-04-07
RU2013121744A (en) 2014-11-20
IL225689A0 (en) 2013-06-27
EP2627321A1 (en) 2013-08-21
AU2017202267A1 (en) 2017-04-27
EP3653206A1 (en) 2020-05-20
EP3132791A1 (en) 2017-02-22
US20130203764A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
DK3132791T3 (en) Inhibition of Metastases with Compounds That Reduce the Persistent Part of the Voltage-Dependent Sodium Channel
DK3239134T3 (en) PYRIDONAMIDES AS MODULARS OF SODIUM CHANNELS
DK3520805T3 (en) COMPOSITIONS FOR THE TREATMENT OF MYELOFIBROSE
DK3466949T3 (en) TRICYCLIC COMPOUND AS ANTICANCY AGENTS
EA201692203A1 (en) TANK-BINDING KINAZ INHIBITING COMPOUNDS
DK2954051T3 (en) MODIFIED KAPSID FOR TRANSFER FOR TREATMENT OF THE NETWORK
CR20140259A (en) NEW BENZOPIRAN COMPOUNDS, COMPOSITIONS AND USES OF THE SAME
DK2693881T3 (en) SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS AXL-KINASE INHIBITORS
EP2681200A4 (en) Benzimidazole inhibitors of the sodium channel
DK3181567T3 (en) Pyrazolopyridamide compounds as kinase inhibitors
DK3590928T3 (en) PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRUS INFECTIONS
DK2315756T3 (en) 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLAMIN-2,3-DIOXYGENASE
DK3003038T3 (en) 2H-1,2,3-TRIAZOLD DERIVATIVES AS FIBROSE INHIBITORS
DK2981535T3 (en) URINE DERIVATIVES USE AS CHINESE INHIBITORS
DK2571963T3 (en) COMPOSITIONS THAT PROVIDE CLEANING PROPERTY
DK3251678T3 (en) BENZOXABOROL DERIVATIVES FOR THE TREATMENT OF BACTERIA INFECTIONS
BR112013019327A2 (en) compound and composition.
DK2658851T3 (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
CL2015000855A1 (en) Composition of compound for joints of dried type, low in water.
DK2797581T3 (en) FORMULATIONS OF (+) - 2- [1- (3-ETHOXY-4-METHOXYPHENYL) -2-METHANSULPHONYLETHYL] -4-ACETYLAMINOISOINDOLINE-1,3-DION
DK3544981T3 (en) BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS
DK3494993T3 (en) NEW USE OF MALTOTRIOSYL TRANSFERASE
EA201590552A1 (en) AMINOHINOLINES AS KINASE INHIBITORS
MA41803A (en) AMINO-INDAZOLES USED AS SODIUM CHANNEL INHIBITORS
EA201490761A1 (en) R (+) - N-Formylpropylglycinone